Thus, while the MTH1-binding capacity of both drugs is not in question8,9,15,16,19,30, the effects on CRC cell survival do not seem to be due to inhibition of MTH1, as they are unaffected by experimental manipulation of ROS levels. The gene discussed is NUDT1; the disease is colorectal carcinoma.